nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—NT5E—embryo—testicular cancer	0.0247	0.122	CbGeAlD
Pentoxifylline—NT5E—gonad—testicular cancer	0.0168	0.0828	CbGeAlD
Pentoxifylline—NT5E—female gonad—testicular cancer	0.0136	0.0673	CbGeAlD
Pentoxifylline—NT5E—testis—testicular cancer	0.0121	0.0597	CbGeAlD
Pentoxifylline—ADORA2A—gonad—testicular cancer	0.012	0.059	CbGeAlD
Pentoxifylline—PDE5A—gonad—testicular cancer	0.0109	0.0537	CbGeAlD
Pentoxifylline—PDE4A—female gonad—testicular cancer	0.0104	0.0513	CbGeAlD
Pentoxifylline—ADORA2B—testis—testicular cancer	0.0104	0.0511	CbGeAlD
Pentoxifylline—PDE4A—testis—testicular cancer	0.00924	0.0455	CbGeAlD
Pentoxifylline—PDE5A—female gonad—testicular cancer	0.00886	0.0437	CbGeAlD
Pentoxifylline—NT5E—lymph node—testicular cancer	0.00878	0.0433	CbGeAlD
Pentoxifylline—ADORA2A—testis—testicular cancer	0.00863	0.0425	CbGeAlD
Pentoxifylline—PDE5A—testis—testicular cancer	0.00786	0.0387	CbGeAlD
Pentoxifylline—PDE4B—gonad—testicular cancer	0.00764	0.0377	CbGeAlD
Pentoxifylline—ADORA1—testis—testicular cancer	0.00745	0.0367	CbGeAlD
Pentoxifylline—PDE4A—lymph node—testicular cancer	0.0067	0.033	CbGeAlD
Pentoxifylline—PDE4B—female gonad—testicular cancer	0.00621	0.0306	CbGeAlD
Pentoxifylline—PDE5A—lymph node—testicular cancer	0.00569	0.0281	CbGeAlD
Pentoxifylline—PDE4B—testis—testicular cancer	0.00551	0.0272	CbGeAlD
Pentoxifylline—ADORA1—lymph node—testicular cancer	0.0054	0.0266	CbGeAlD
Pentoxifylline—PDE4B—lymph node—testicular cancer	0.00399	0.0197	CbGeAlD
Pentoxifylline—NT5E—Differentiation Pathway—KITLG—testicular cancer	0.00378	0.0928	CbGpPWpGaD
Pentoxifylline—ADORA2B—G alpha (s) signalling events—INSL3—testicular cancer	0.00304	0.0746	CbGpPWpGaD
Pentoxifylline—PDE4A—G alpha (s) signalling events—INSL3—testicular cancer	0.00276	0.0677	CbGpPWpGaD
Pentoxifylline—NT5E—Differentiation Pathway—KIT—testicular cancer	0.00258	0.0633	CbGpPWpGaD
Pentoxifylline—PDE4B—G alpha (s) signalling events—INSL3—testicular cancer	0.00256	0.0627	CbGpPWpGaD
Pentoxifylline—ADORA2A—G alpha (s) signalling events—INSL3—testicular cancer	0.002	0.049	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00191	0.0468	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00145	0.0356	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00133	0.0326	CbGpPWpGaD
Pentoxifylline—Asthenia—Dactinomycin—testicular cancer	0.00133	0.00175	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Etoposide—testicular cancer	0.00131	0.00173	CcSEcCtD
Pentoxifylline—Tachycardia—Etoposide—testicular cancer	0.00131	0.00173	CcSEcCtD
Pentoxifylline—Dyspnoea—Cisplatin—testicular cancer	0.0013	0.00172	CcSEcCtD
Pentoxifylline—Skin disorder—Etoposide—testicular cancer	0.0013	0.00172	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Etoposide—testicular cancer	0.00129	0.00171	CcSEcCtD
Pentoxifylline—Angina pectoris—Epirubicin—testicular cancer	0.00128	0.0017	CcSEcCtD
Pentoxifylline—Anorexia—Etoposide—testicular cancer	0.00127	0.00169	CcSEcCtD
Pentoxifylline—Decreased appetite—Cisplatin—testicular cancer	0.00127	0.00168	CcSEcCtD
Pentoxifylline—Diarrhoea—Dactinomycin—testicular cancer	0.00126	0.00167	CcSEcCtD
Pentoxifylline—Vomiting—Bleomycin—testicular cancer	0.00126	0.00167	CcSEcCtD
Pentoxifylline—Infestation NOS—Methotrexate—testicular cancer	0.00126	0.00166	CcSEcCtD
Pentoxifylline—Drowsiness—Methotrexate—testicular cancer	0.00126	0.00166	CcSEcCtD
Pentoxifylline—Infestation—Methotrexate—testicular cancer	0.00126	0.00166	CcSEcCtD
Pentoxifylline—Pancytopenia—Epirubicin—testicular cancer	0.00125	0.00166	CcSEcCtD
Pentoxifylline—Hypotension—Etoposide—testicular cancer	0.00125	0.00165	CcSEcCtD
Pentoxifylline—Rash—Bleomycin—testicular cancer	0.00125	0.00165	CcSEcCtD
Pentoxifylline—Dermatitis—Bleomycin—testicular cancer	0.00125	0.00165	CcSEcCtD
Pentoxifylline—Hypersensitivity—Ifosfamide—testicular cancer	0.00125	0.00165	CcSEcCtD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00123	0.0302	CbGpPWpGaD
Pentoxifylline—Abdominal distension—Doxorubicin—testicular cancer	0.00123	0.00162	CcSEcCtD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—KITLG—testicular cancer	0.00122	0.03	CbGpPWpGaD
Pentoxifylline—Conjunctivitis—Methotrexate—testicular cancer	0.00122	0.00161	CcSEcCtD
Pentoxifylline—Asthenia—Ifosfamide—testicular cancer	0.00121	0.00161	CcSEcCtD
Pentoxifylline—Sweating—Methotrexate—testicular cancer	0.0012	0.00159	CcSEcCtD
Pentoxifylline—Feeling abnormal—Cisplatin—testicular cancer	0.0012	0.00159	CcSEcCtD
Pentoxifylline—Pruritus—Ifosfamide—testicular cancer	0.0012	0.00158	CcSEcCtD
Pentoxifylline—Dyspnoea—Etoposide—testicular cancer	0.00119	0.00158	CcSEcCtD
Pentoxifylline—Somnolence—Etoposide—testicular cancer	0.00119	0.00157	CcSEcCtD
Pentoxifylline—Angina pectoris—Doxorubicin—testicular cancer	0.00119	0.00157	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Methotrexate—testicular cancer	0.00119	0.00157	CcSEcCtD
Pentoxifylline—Epistaxis—Methotrexate—testicular cancer	0.00118	0.00157	CcSEcCtD
Pentoxifylline—Nausea—Bleomycin—testicular cancer	0.00118	0.00156	CcSEcCtD
Pentoxifylline—Drowsiness—Epirubicin—testicular cancer	0.00118	0.00155	CcSEcCtD
Pentoxifylline—Infestation NOS—Epirubicin—testicular cancer	0.00118	0.00155	CcSEcCtD
Pentoxifylline—Infestation—Epirubicin—testicular cancer	0.00118	0.00155	CcSEcCtD
Pentoxifylline—Vomiting—Dactinomycin—testicular cancer	0.00117	0.00155	CcSEcCtD
Pentoxifylline—Rash—Dactinomycin—testicular cancer	0.00116	0.00154	CcSEcCtD
Pentoxifylline—Decreased appetite—Etoposide—testicular cancer	0.00116	0.00154	CcSEcCtD
Pentoxifylline—Diarrhoea—Ifosfamide—testicular cancer	0.00116	0.00153	CcSEcCtD
Pentoxifylline—Pancytopenia—Doxorubicin—testicular cancer	0.00116	0.00153	CcSEcCtD
Pentoxifylline—Body temperature increased—Cisplatin—testicular cancer	0.00115	0.00153	CcSEcCtD
Pentoxifylline—Jaundice—Epirubicin—testicular cancer	0.00115	0.00151	CcSEcCtD
Pentoxifylline—Constipation—Etoposide—testicular cancer	0.00114	0.00151	CcSEcCtD
Pentoxifylline—Conjunctivitis—Epirubicin—testicular cancer	0.00114	0.00151	CcSEcCtD
Pentoxifylline—Haemoglobin—Methotrexate—testicular cancer	0.00113	0.0015	CcSEcCtD
Pentoxifylline—Haemorrhage—Methotrexate—testicular cancer	0.00113	0.00149	CcSEcCtD
Pentoxifylline—Hepatitis—Methotrexate—testicular cancer	0.00113	0.00149	CcSEcCtD
Pentoxifylline—Sweating—Epirubicin—testicular cancer	0.00113	0.00149	CcSEcCtD
Pentoxifylline—Dizziness—Ifosfamide—testicular cancer	0.00112	0.00148	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Epirubicin—testicular cancer	0.00111	0.00147	CcSEcCtD
Pentoxifylline—Epistaxis—Epirubicin—testicular cancer	0.00111	0.00147	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—INSL3—testicular cancer	0.0011	0.0271	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Etoposide—testicular cancer	0.0011	0.00146	CcSEcCtD
Pentoxifylline—Nausea—Dactinomycin—testicular cancer	0.0011	0.00145	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Etoposide—testicular cancer	0.00109	0.00145	CcSEcCtD
Pentoxifylline—Infestation—Doxorubicin—testicular cancer	0.00109	0.00144	CcSEcCtD
Pentoxifylline—Infestation NOS—Doxorubicin—testicular cancer	0.00109	0.00144	CcSEcCtD
Pentoxifylline—Drowsiness—Doxorubicin—testicular cancer	0.00109	0.00144	CcSEcCtD
Pentoxifylline—Vomiting—Ifosfamide—testicular cancer	0.00108	0.00142	CcSEcCtD
Pentoxifylline—Hypersensitivity—Cisplatin—testicular cancer	0.00108	0.00142	CcSEcCtD
Pentoxifylline—Rash—Ifosfamide—testicular cancer	0.00107	0.00141	CcSEcCtD
Pentoxifylline—Dermatitis—Ifosfamide—testicular cancer	0.00107	0.00141	CcSEcCtD
Pentoxifylline—Urticaria—Etoposide—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Haemoglobin—Epirubicin—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Jaundice—Doxorubicin—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Abdominal pain—Etoposide—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Body temperature increased—Etoposide—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Conjunctivitis—Doxorubicin—testicular cancer	0.00106	0.0014	CcSEcCtD
Pentoxifylline—Hepatitis—Epirubicin—testicular cancer	0.00106	0.00139	CcSEcCtD
Pentoxifylline—Haemorrhage—Epirubicin—testicular cancer	0.00106	0.00139	CcSEcCtD
Pentoxifylline—Asthenia—Cisplatin—testicular cancer	0.00105	0.00138	CcSEcCtD
Pentoxifylline—Sweating—Doxorubicin—testicular cancer	0.00104	0.00138	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00103	0.00136	CcSEcCtD
Pentoxifylline—Epistaxis—Doxorubicin—testicular cancer	0.00103	0.00136	CcSEcCtD
Pentoxifylline—Immune system disorder—Methotrexate—testicular cancer	0.00102	0.00135	CcSEcCtD
Pentoxifylline—Nausea—Ifosfamide—testicular cancer	0.00101	0.00133	CcSEcCtD
Pentoxifylline—Diarrhoea—Cisplatin—testicular cancer	0.000999	0.00132	CcSEcCtD
Pentoxifylline—Hypersensitivity—Etoposide—testicular cancer	0.000985	0.0013	CcSEcCtD
Pentoxifylline—Erythema—Methotrexate—testicular cancer	0.000981	0.0013	CcSEcCtD
Pentoxifylline—Haemoglobin—Doxorubicin—testicular cancer	0.000981	0.0013	CcSEcCtD
Pentoxifylline—Flushing—Epirubicin—testicular cancer	0.000979	0.00129	CcSEcCtD
Pentoxifylline—Haemorrhage—Doxorubicin—testicular cancer	0.000976	0.00129	CcSEcCtD
Pentoxifylline—Hepatitis—Doxorubicin—testicular cancer	0.000976	0.00129	CcSEcCtD
Pentoxifylline—Dysgeusia—Methotrexate—testicular cancer	0.000961	0.00127	CcSEcCtD
Pentoxifylline—Asthenia—Etoposide—testicular cancer	0.000959	0.00127	CcSEcCtD
Pentoxifylline—Immune system disorder—Epirubicin—testicular cancer	0.000953	0.00126	CcSEcCtD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000952	0.0233	CbGpPWpGaD
Pentoxifylline—Back pain—Methotrexate—testicular cancer	0.000949	0.00126	CcSEcCtD
Pentoxifylline—Pruritus—Etoposide—testicular cancer	0.000946	0.00125	CcSEcCtD
Pentoxifylline—Arrhythmia—Epirubicin—testicular cancer	0.000942	0.00125	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—INSL3—testicular cancer	0.000939	0.023	CbGpPWpGaD
Pentoxifylline—Vomiting—Cisplatin—testicular cancer	0.000928	0.00123	CcSEcCtD
Pentoxifylline—Vision blurred—Methotrexate—testicular cancer	0.000925	0.00122	CcSEcCtD
Pentoxifylline—Rash—Cisplatin—testicular cancer	0.00092	0.00122	CcSEcCtD
Pentoxifylline—Dermatitis—Cisplatin—testicular cancer	0.000919	0.00122	CcSEcCtD
Pentoxifylline—Erythema—Epirubicin—testicular cancer	0.000918	0.00121	CcSEcCtD
Pentoxifylline—Diarrhoea—Etoposide—testicular cancer	0.000915	0.00121	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Methotrexate—testicular cancer	0.000911	0.0012	CcSEcCtD
Pentoxifylline—Anaemia—Methotrexate—testicular cancer	0.000907	0.0012	CcSEcCtD
Pentoxifylline—Flushing—Doxorubicin—testicular cancer	0.000906	0.0012	CcSEcCtD
Pentoxifylline—Flatulence—Epirubicin—testicular cancer	0.000905	0.0012	CcSEcCtD
Pentoxifylline—Tension—Epirubicin—testicular cancer	0.000901	0.00119	CcSEcCtD
Pentoxifylline—Dysgeusia—Epirubicin—testicular cancer	0.000899	0.00119	CcSEcCtD
Pentoxifylline—Nervousness—Epirubicin—testicular cancer	0.000892	0.00118	CcSEcCtD
Pentoxifylline—Back pain—Epirubicin—testicular cancer	0.000888	0.00117	CcSEcCtD
Pentoxifylline—Malaise—Methotrexate—testicular cancer	0.000885	0.00117	CcSEcCtD
Pentoxifylline—Dizziness—Etoposide—testicular cancer	0.000884	0.00117	CcSEcCtD
Pentoxifylline—Muscle spasms—Epirubicin—testicular cancer	0.000883	0.00117	CcSEcCtD
Pentoxifylline—Immune system disorder—Doxorubicin—testicular cancer	0.000882	0.00117	CcSEcCtD
Pentoxifylline—Leukopenia—Methotrexate—testicular cancer	0.000878	0.00116	CcSEcCtD
Pentoxifylline—Arrhythmia—Doxorubicin—testicular cancer	0.000872	0.00115	CcSEcCtD
Pentoxifylline—Nausea—Cisplatin—testicular cancer	0.000867	0.00115	CcSEcCtD
Pentoxifylline—Vision blurred—Epirubicin—testicular cancer	0.000866	0.00114	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Epirubicin—testicular cancer	0.000852	0.00113	CcSEcCtD
Pentoxifylline—Convulsion—Methotrexate—testicular cancer	0.00085	0.00112	CcSEcCtD
Pentoxifylline—Vomiting—Etoposide—testicular cancer	0.00085	0.00112	CcSEcCtD
Pentoxifylline—Erythema—Doxorubicin—testicular cancer	0.00085	0.00112	CcSEcCtD
Pentoxifylline—Anaemia—Epirubicin—testicular cancer	0.000849	0.00112	CcSEcCtD
Pentoxifylline—Agitation—Epirubicin—testicular cancer	0.000844	0.00112	CcSEcCtD
Pentoxifylline—Rash—Etoposide—testicular cancer	0.000843	0.00111	CcSEcCtD
Pentoxifylline—Dermatitis—Etoposide—testicular cancer	0.000842	0.00111	CcSEcCtD
Pentoxifylline—Headache—Etoposide—testicular cancer	0.000838	0.00111	CcSEcCtD
Pentoxifylline—Flatulence—Doxorubicin—testicular cancer	0.000837	0.00111	CcSEcCtD
Pentoxifylline—Chest pain—Methotrexate—testicular cancer	0.000836	0.0011	CcSEcCtD
Pentoxifylline—Myalgia—Methotrexate—testicular cancer	0.000836	0.0011	CcSEcCtD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—KIT—testicular cancer	0.000834	0.0205	CbGpPWpGaD
Pentoxifylline—Tension—Doxorubicin—testicular cancer	0.000834	0.0011	CcSEcCtD
Pentoxifylline—Dysgeusia—Doxorubicin—testicular cancer	0.000832	0.0011	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00083	0.0011	CcSEcCtD
Pentoxifylline—Malaise—Epirubicin—testicular cancer	0.000828	0.0011	CcSEcCtD
Pentoxifylline—Discomfort—Methotrexate—testicular cancer	0.000826	0.00109	CcSEcCtD
Pentoxifylline—Nervousness—Doxorubicin—testicular cancer	0.000825	0.00109	CcSEcCtD
Pentoxifylline—Leukopenia—Epirubicin—testicular cancer	0.000822	0.00109	CcSEcCtD
Pentoxifylline—Back pain—Doxorubicin—testicular cancer	0.000822	0.00109	CcSEcCtD
Pentoxifylline—Muscle spasms—Doxorubicin—testicular cancer	0.000817	0.00108	CcSEcCtD
Pentoxifylline—Palpitations—Epirubicin—testicular cancer	0.000812	0.00107	CcSEcCtD
Pentoxifylline—Confusional state—Methotrexate—testicular cancer	0.000808	0.00107	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Methotrexate—testicular cancer	0.000801	0.00106	CcSEcCtD
Pentoxifylline—Vision blurred—Doxorubicin—testicular cancer	0.000801	0.00106	CcSEcCtD
Pentoxifylline—Convulsion—Epirubicin—testicular cancer	0.000796	0.00105	CcSEcCtD
Pentoxifylline—Infection—Methotrexate—testicular cancer	0.000796	0.00105	CcSEcCtD
Pentoxifylline—Nausea—Etoposide—testicular cancer	0.000794	0.00105	CcSEcCtD
Pentoxifylline—Hypertension—Epirubicin—testicular cancer	0.000793	0.00105	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Doxorubicin—testicular cancer	0.000788	0.00104	CcSEcCtD
Pentoxifylline—Anaemia—Doxorubicin—testicular cancer	0.000785	0.00104	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Methotrexate—testicular cancer	0.000784	0.00104	CcSEcCtD
Pentoxifylline—Chest pain—Epirubicin—testicular cancer	0.000782	0.00103	CcSEcCtD
Pentoxifylline—Myalgia—Epirubicin—testicular cancer	0.000782	0.00103	CcSEcCtD
Pentoxifylline—Agitation—Doxorubicin—testicular cancer	0.000781	0.00103	CcSEcCtD
Pentoxifylline—Anxiety—Epirubicin—testicular cancer	0.000779	0.00103	CcSEcCtD
Pentoxifylline—Skin disorder—Methotrexate—testicular cancer	0.000778	0.00103	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000777	0.00103	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Methotrexate—testicular cancer	0.000774	0.00102	CcSEcCtD
Pentoxifylline—Discomfort—Epirubicin—testicular cancer	0.000773	0.00102	CcSEcCtD
Pentoxifylline—Malaise—Doxorubicin—testicular cancer	0.000766	0.00101	CcSEcCtD
Pentoxifylline—Dry mouth—Epirubicin—testicular cancer	0.000765	0.00101	CcSEcCtD
Pentoxifylline—Anorexia—Methotrexate—testicular cancer	0.000763	0.00101	CcSEcCtD
Pentoxifylline—Leukopenia—Doxorubicin—testicular cancer	0.000761	0.00101	CcSEcCtD
Pentoxifylline—Confusional state—Epirubicin—testicular cancer	0.000756	0.000999	CcSEcCtD
Pentoxifylline—Palpitations—Doxorubicin—testicular cancer	0.000751	0.000993	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Epirubicin—testicular cancer	0.00075	0.000991	CcSEcCtD
Pentoxifylline—Oedema—Epirubicin—testicular cancer	0.00075	0.000991	CcSEcCtD
Pentoxifylline—Hypotension—Methotrexate—testicular cancer	0.000748	0.00099	CcSEcCtD
Pentoxifylline—Infection—Epirubicin—testicular cancer	0.000745	0.000985	CcSEcCtD
Pentoxifylline—Shock—Epirubicin—testicular cancer	0.000737	0.000975	CcSEcCtD
Pentoxifylline—Convulsion—Doxorubicin—testicular cancer	0.000736	0.000973	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Epirubicin—testicular cancer	0.000734	0.00097	CcSEcCtD
Pentoxifylline—Hypertension—Doxorubicin—testicular cancer	0.000734	0.00097	CcSEcCtD
Pentoxifylline—Tachycardia—Epirubicin—testicular cancer	0.000732	0.000967	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00073	0.000965	CcSEcCtD
Pentoxifylline—Skin disorder—Epirubicin—testicular cancer	0.000728	0.000963	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—INSL3—testicular cancer	0.000725	0.0178	CbGpPWpGaD
Pentoxifylline—Hyperhidrosis—Epirubicin—testicular cancer	0.000725	0.000958	CcSEcCtD
Pentoxifylline—Insomnia—Methotrexate—testicular cancer	0.000724	0.000958	CcSEcCtD
Pentoxifylline—Chest pain—Doxorubicin—testicular cancer	0.000723	0.000957	CcSEcCtD
Pentoxifylline—Myalgia—Doxorubicin—testicular cancer	0.000723	0.000957	CcSEcCtD
Pentoxifylline—Anxiety—Doxorubicin—testicular cancer	0.000721	0.000953	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000718	0.00095	CcSEcCtD
Pentoxifylline—Discomfort—Doxorubicin—testicular cancer	0.000715	0.000945	CcSEcCtD
Pentoxifylline—Anorexia—Epirubicin—testicular cancer	0.000714	0.000945	CcSEcCtD
Pentoxifylline—Dyspnoea—Methotrexate—testicular cancer	0.000714	0.000944	CcSEcCtD
Pentoxifylline—Somnolence—Methotrexate—testicular cancer	0.000712	0.000941	CcSEcCtD
Pentoxifylline—Dry mouth—Doxorubicin—testicular cancer	0.000708	0.000936	CcSEcCtD
Pentoxifylline—Dyspepsia—Methotrexate—testicular cancer	0.000705	0.000932	CcSEcCtD
Pentoxifylline—Hypotension—Epirubicin—testicular cancer	0.0007	0.000926	CcSEcCtD
Pentoxifylline—Confusional state—Doxorubicin—testicular cancer	0.000699	0.000925	CcSEcCtD
Pentoxifylline—Decreased appetite—Methotrexate—testicular cancer	0.000696	0.000921	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Doxorubicin—testicular cancer	0.000694	0.000917	CcSEcCtD
Pentoxifylline—Oedema—Doxorubicin—testicular cancer	0.000694	0.000917	CcSEcCtD
Pentoxifylline—Infection—Doxorubicin—testicular cancer	0.000689	0.000911	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000683	0.000903	CcSEcCtD
Pentoxifylline—Shock—Doxorubicin—testicular cancer	0.000682	0.000902	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Doxorubicin—testicular cancer	0.000679	0.000898	CcSEcCtD
Pentoxifylline—Insomnia—Epirubicin—testicular cancer	0.000678	0.000896	CcSEcCtD
Pentoxifylline—Tachycardia—Doxorubicin—testicular cancer	0.000677	0.000895	CcSEcCtD
Pentoxifylline—Skin disorder—Doxorubicin—testicular cancer	0.000674	0.000891	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Doxorubicin—testicular cancer	0.00067	0.000886	CcSEcCtD
Pentoxifylline—Dyspnoea—Epirubicin—testicular cancer	0.000668	0.000884	CcSEcCtD
Pentoxifylline—Somnolence—Epirubicin—testicular cancer	0.000666	0.000881	CcSEcCtD
Pentoxifylline—Anorexia—Doxorubicin—testicular cancer	0.000661	0.000874	CcSEcCtD
Pentoxifylline—Feeling abnormal—Methotrexate—testicular cancer	0.00066	0.000873	CcSEcCtD
Pentoxifylline—Dyspepsia—Epirubicin—testicular cancer	0.00066	0.000872	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Methotrexate—testicular cancer	0.000655	0.000866	CcSEcCtD
Pentoxifylline—Decreased appetite—Epirubicin—testicular cancer	0.000652	0.000862	CcSEcCtD
Pentoxifylline—Hypotension—Doxorubicin—testicular cancer	0.000648	0.000857	CcSEcCtD
Pentoxifylline—Constipation—Epirubicin—testicular cancer	0.000641	0.000847	CcSEcCtD
Pentoxifylline—Urticaria—Methotrexate—testicular cancer	0.000636	0.000841	CcSEcCtD
Pentoxifylline—Abdominal pain—Methotrexate—testicular cancer	0.000633	0.000837	CcSEcCtD
Pentoxifylline—Body temperature increased—Methotrexate—testicular cancer	0.000633	0.000837	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000632	0.000835	CcSEcCtD
Pentoxifylline—Insomnia—Doxorubicin—testicular cancer	0.000627	0.000829	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR downstream signaling—INSL3—testicular cancer	0.000624	0.0153	CbGpPWpGaD
Pentoxifylline—Dyspnoea—Doxorubicin—testicular cancer	0.000618	0.000818	CcSEcCtD
Pentoxifylline—Feeling abnormal—Epirubicin—testicular cancer	0.000618	0.000817	CcSEcCtD
Pentoxifylline—Somnolence—Doxorubicin—testicular cancer	0.000617	0.000815	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Epirubicin—testicular cancer	0.000613	0.00081	CcSEcCtD
Pentoxifylline—Dyspepsia—Doxorubicin—testicular cancer	0.00061	0.000807	CcSEcCtD
Pentoxifylline—Decreased appetite—Doxorubicin—testicular cancer	0.000603	0.000797	CcSEcCtD
Pentoxifylline—Urticaria—Epirubicin—testicular cancer	0.000595	0.000787	CcSEcCtD
Pentoxifylline—Constipation—Doxorubicin—testicular cancer	0.000593	0.000784	CcSEcCtD
Pentoxifylline—Abdominal pain—Epirubicin—testicular cancer	0.000593	0.000783	CcSEcCtD
Pentoxifylline—Body temperature increased—Epirubicin—testicular cancer	0.000593	0.000783	CcSEcCtD
Pentoxifylline—Hypersensitivity—Methotrexate—testicular cancer	0.00059	0.00078	CcSEcCtD
Pentoxifylline—Asthenia—Methotrexate—testicular cancer	0.000575	0.00076	CcSEcCtD
Pentoxifylline—Feeling abnormal—Doxorubicin—testicular cancer	0.000572	0.000756	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000567	0.00075	CcSEcCtD
Pentoxifylline—Pruritus—Methotrexate—testicular cancer	0.000567	0.000749	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling by GPCR—INSL3—testicular cancer	0.000567	0.0139	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—INSL3—testicular cancer	0.000567	0.0139	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Epirubicin—testicular cancer	0.000552	0.00073	CcSEcCtD
Pentoxifylline—Urticaria—Doxorubicin—testicular cancer	0.000551	0.000728	CcSEcCtD
Pentoxifylline—Body temperature increased—Doxorubicin—testicular cancer	0.000548	0.000725	CcSEcCtD
Pentoxifylline—Abdominal pain—Doxorubicin—testicular cancer	0.000548	0.000725	CcSEcCtD
Pentoxifylline—Diarrhoea—Methotrexate—testicular cancer	0.000548	0.000725	CcSEcCtD
Pentoxifylline—Asthenia—Epirubicin—testicular cancer	0.000538	0.000711	CcSEcCtD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000537	0.0132	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—INSL3—testicular cancer	0.000531	0.013	CbGpPWpGaD
Pentoxifylline—Pruritus—Epirubicin—testicular cancer	0.00053	0.000701	CcSEcCtD
Pentoxifylline—Dizziness—Methotrexate—testicular cancer	0.00053	0.0007	CcSEcCtD
Pentoxifylline—PDE4B—GPCR downstream signaling—INSL3—testicular cancer	0.000524	0.0129	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—INSL3—testicular cancer	0.000515	0.0126	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Epirubicin—testicular cancer	0.000513	0.000678	CcSEcCtD
Pentoxifylline—Hypersensitivity—Doxorubicin—testicular cancer	0.000511	0.000676	CcSEcCtD
Pentoxifylline—Vomiting—Methotrexate—testicular cancer	0.000509	0.000673	CcSEcCtD
Pentoxifylline—Rash—Methotrexate—testicular cancer	0.000505	0.000668	CcSEcCtD
Pentoxifylline—Dermatitis—Methotrexate—testicular cancer	0.000505	0.000667	CcSEcCtD
Pentoxifylline—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000502	0.0123	CbGpPWpGaD
Pentoxifylline—Headache—Methotrexate—testicular cancer	0.000502	0.000663	CcSEcCtD
Pentoxifylline—Asthenia—Doxorubicin—testicular cancer	0.000498	0.000658	CcSEcCtD
Pentoxifylline—Dizziness—Epirubicin—testicular cancer	0.000496	0.000655	CcSEcCtD
Pentoxifylline—Pruritus—Doxorubicin—testicular cancer	0.000491	0.000649	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—INSL3—testicular cancer	0.000482	0.0118	CbGpPWpGaD
Pentoxifylline—Vomiting—Epirubicin—testicular cancer	0.000477	0.00063	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—INSL3—testicular cancer	0.000476	0.0117	CbGpPWpGaD
Pentoxifylline—Nausea—Methotrexate—testicular cancer	0.000476	0.000629	CcSEcCtD
Pentoxifylline—Diarrhoea—Doxorubicin—testicular cancer	0.000475	0.000627	CcSEcCtD
Pentoxifylline—Rash—Epirubicin—testicular cancer	0.000473	0.000625	CcSEcCtD
Pentoxifylline—Dermatitis—Epirubicin—testicular cancer	0.000472	0.000624	CcSEcCtD
Pentoxifylline—Headache—Epirubicin—testicular cancer	0.00047	0.000621	CcSEcCtD
Pentoxifylline—Dizziness—Doxorubicin—testicular cancer	0.000459	0.000606	CcSEcCtD
Pentoxifylline—Nausea—Epirubicin—testicular cancer	0.000445	0.000589	CcSEcCtD
Pentoxifylline—Vomiting—Doxorubicin—testicular cancer	0.000441	0.000583	CcSEcCtD
Pentoxifylline—Rash—Doxorubicin—testicular cancer	0.000437	0.000578	CcSEcCtD
Pentoxifylline—Dermatitis—Doxorubicin—testicular cancer	0.000437	0.000578	CcSEcCtD
Pentoxifylline—Headache—Doxorubicin—testicular cancer	0.000434	0.000574	CcSEcCtD
Pentoxifylline—Nausea—Doxorubicin—testicular cancer	0.000412	0.000545	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR downstream signaling—INSL3—testicular cancer	0.00041	0.01	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000392	0.00961	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—INSL3—testicular cancer	0.000372	0.00912	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—HPGDS—testicular cancer	0.000347	0.0085	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—INSL3—testicular cancer	0.000335	0.00821	CbGpPWpGaD
Pentoxifylline—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000319	0.00783	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—INSL3—testicular cancer	0.000304	0.00745	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—KITLG—testicular cancer	0.000301	0.00739	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000291	0.00714	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—INSL3—testicular cancer	0.000285	0.00698	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—INSL3—testicular cancer	0.000281	0.0069	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000267	0.00655	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—STK11—testicular cancer	0.000252	0.00618	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—FGFR3—testicular cancer	0.000224	0.00549	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—INSL3—testicular cancer	0.00022	0.00539	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—KIT—testicular cancer	0.000206	0.00504	CbGpPWpGaD
Pentoxifylline—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000187	0.00458	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—H2AFZ—testicular cancer	0.000107	0.00263	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STK11—testicular cancer	0.000107	0.00261	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KITLG—testicular cancer	9.86e-05	0.00242	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—H2AFZ—testicular cancer	9.73e-05	0.00239	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STK11—testicular cancer	9.67e-05	0.00237	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—H2AFZ—testicular cancer	9.11e-05	0.00223	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STK11—testicular cancer	9.06e-05	0.00222	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—H2AFZ—testicular cancer	9e-05	0.00221	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STK11—testicular cancer	8.95e-05	0.00219	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KITLG—testicular cancer	8.95e-05	0.00219	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KITLG—testicular cancer	8.38e-05	0.00206	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KITLG—testicular cancer	8.28e-05	0.00203	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—FGFR3—testicular cancer	7.33e-05	0.0018	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.17e-05	0.00176	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—H2AFZ—testicular cancer	7.03e-05	0.00172	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STK11—testicular cancer	6.99e-05	0.00171	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KIT—testicular cancer	6.73e-05	0.00165	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—FGFR3—testicular cancer	6.65e-05	0.00163	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KITLG—testicular cancer	6.47e-05	0.00159	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—FGFR3—testicular cancer	6.23e-05	0.00153	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—FGFR3—testicular cancer	6.16e-05	0.00151	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KIT—testicular cancer	6.11e-05	0.0015	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KIT—testicular cancer	5.72e-05	0.0014	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KIT—testicular cancer	5.65e-05	0.00139	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FGFR3—testicular cancer	4.81e-05	0.00118	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KIT—testicular cancer	4.42e-05	0.00108	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HPGDS—testicular cancer	3.19e-05	0.000783	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—STK11—testicular cancer	2.32e-05	0.000569	CbGpPWpGaD
